Regulation and function of the YAP transcription co-activator oncoprotein
YAP转录辅激活癌蛋白的调控和功能
基本信息
- 批准号:8022881
- 负责人:
- 金额:$ 31.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-04-08 至 2013-02-28
- 项目状态:已结题
- 来源:
- 关键词:11q22ApoptosisCancer Cell Growth RegulationCell DeathCell ProliferationCell Proliferation RegulationCell physiologyCellsContact InhibitionCyclin EDataDevelopmentDrosophila genusEpithelialGene ExpressionGene Expression RegulationGene TargetingGeneticGenetic TranscriptionGoalsHomologous GeneHumanHuman ChromosomesHuman DevelopmentInhibition of ApoptosisMalignant NeoplasmsMalignant neoplasm of liverMalignant neoplasm of prostateMammalian CellMediatingMesenchymalMicroRNAsMolecularMutationNeurofibromatosis 2Oncogene ProteinsOncogenesOncogenicOrgan SizePRDM4 genePathway interactionsPhosphorylation InhibitionPlayProtein KinaseProteinsRegulationRoleSignal PathwayTestingTumor Suppressor ProteinsWorkcIAP1 proteinmembermutantnovelprotein functionpublic health relevanceresponsetranscription factortumorigenesis
项目摘要
DESCRIPTION (provided by applicant): Regulation and function of the YAP transcription co-activator oncoprotein
The yes-associated protein YAP is a potent transcription co-activator. Recent genetic studies have implicated YAP as a candidate oncogene in human chromosome 11q22 amplicon. Drosophila studies have established a novel tumor suppressor pathway Hippo that regulates both cell proliferation and apoptosis. Many components of the Hippo pathway are highly conserved. YAP is likely to be the major target inhibited by the Hippo pathway. YAP can functionally rescue yorkie (the Drosophila homolog of mammalian YAP) mutation in Drosophila. It has been suggested that the neurofibromatosis 2 (NF2) tumor suppressor is a component of the Hippo pathway acting upstream of YAP to inhibit YAP function. However, the Hippo pathway has not been investigated in mammalian cells. The long term goals of this project are to determine the function and regulation of the Hippo pathway in development of human cancers. Our preliminary data have shown that the Hippo-YAP pathway plays an essential role in cell contact inhibition and oncogenic transformation. Furthermore, YAP is highly elevated in human cancers, including prostate and liver cancers. The specific aims of this proposal are:
1. To identify and characterize YAP target transcription factors
2. To determine the function of YAP target transcription factors in cell contact inhibition, oncogenic transformation, and epithelial-mesenchymal transition
3. To determine the function of YAP-induced micro RNA
Public Health Relevance: YAP is a transcription co-activator and oncogene highly elevated in human cancers. This proposal will study the molecular mechanism of YAP in tumorigenesis by promoting cell proliferation and inhibiting cell death.
描述(由申请人提供):YAP转录共激活剂的调节和功能
与是相关的蛋白质YAP是有效的转录共激活因子。最近的遗传研究已暗示了YAP作为人类染色体11q22扩增子中的候选癌基因。果蝇研究已经建立了一种新型的肿瘤抑制途径,可以调节细胞增殖和凋亡。河马途径的许多组成部分都是高度保守的。 YAP可能是河马途径抑制的主要目标。 YAP可以在果蝇中功能营救约克(哺乳动物YAP的果蝇同源物)。已经提出,神经纤维瘤病2(NF2)肿瘤抑制剂是hippo途径的组成部分,在YAP上游作用以抑制YAP功能。但是,尚未在哺乳动物细胞中研究河马途径。该项目的长期目标是确定人类癌症发展中河马途径的功能和调节。我们的初步数据表明,HIPPO-YAP途径在细胞接触抑制和致癌转化中起着至关重要的作用。此外,在包括前列腺和肝癌在内的人类癌症中,YAP高度升高。该提案的具体目的是:
1。识别和表征YAP目标转录因子
2。确定YAP目标转录因子在细胞接触抑制,致癌转化和上皮 - 间质转变中的功能
3。确定YAP诱导的微RNA的功能
公共卫生相关性:YAP是人类癌症中高度升高的转录共同激活剂和癌基因。该建议将通过促进细胞增殖和抑制细胞死亡来研究肿瘤发生中YAP的分子机制。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Kun-Liang Guan其他文献
Kun-Liang Guan的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Kun-Liang Guan', 18)}}的其他基金
Functional interplay between Hippo and estrogen receptor ESR1
Hippo 和雌激素受体 ESR1 之间的功能相互作用
- 批准号:
10339901 - 财政年份:2022
- 资助金额:
$ 31.1万 - 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
- 批准号:
9453662 - 财政年份:2017
- 资助金额:
$ 31.1万 - 项目类别:
Molecular Mechanism and Therapy for Ocular Melanoma
眼部黑色素瘤的分子机制及治疗
- 批准号:
9328539 - 财政年份:2017
- 资助金额:
$ 31.1万 - 项目类别:
The mTOR and Hippo pathway in cell growth and cancer
mTOR 和 Hippo 通路在细胞生长和癌症中的作用
- 批准号:
9752481 - 财政年份:2015
- 资助金额:
$ 31.1万 - 项目类别:
The mTOR and Hippo pathway in cell growth and cancer
mTOR 和 Hippo 通路在细胞生长和癌症中的作用
- 批准号:
9120339 - 财政年份:2015
- 资助金额:
$ 31.1万 - 项目类别:
Regulation of the Hippo pathway and its role in uveal melanoma
Hippo通路的调节及其在葡萄膜黑色素瘤中的作用
- 批准号:
8722567 - 财政年份:2012
- 资助金额:
$ 31.1万 - 项目类别:
Regulation of the Hippo pathway and its role in uveal melanoma
Hippo通路的调节及其在葡萄膜黑色素瘤中的作用
- 批准号:
8529541 - 财政年份:2012
- 资助金额:
$ 31.1万 - 项目类别:
Regulation of the Hippo pathway and its role in uveal melanoma
Hippo通路的调节及其在葡萄膜黑色素瘤中的作用
- 批准号:
8340411 - 财政年份:2012
- 资助金额:
$ 31.1万 - 项目类别:
Protein phosphorylation and growth factor function
蛋白质磷酸化和生长因子功能
- 批准号:
7892688 - 财政年份:2009
- 资助金额:
$ 31.1万 - 项目类别:
Regulation and function of the YAP transcription co-activator oncoprotein
YAP转录辅激活癌蛋白的调控和功能
- 批准号:
8627562 - 财政年份:2008
- 资助金额:
$ 31.1万 - 项目类别:
相似国自然基金
基于巨噬细胞表型转变探讨BTSA1诱导衰老肌成纤维细胞凋亡及促肺纤维化消退的机制
- 批准号:82370077
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
STAB1调控Fas/FasL介导牦牛胎盘滋养层细胞凋亡及胎盘炎症性流产的作用与机制研究
- 批准号:32360836
- 批准年份:2023
- 资助金额:32 万元
- 项目类别:地区科学基金项目
ATAD3A琥珀酰化调控mtDNA损伤-泛凋亡反应轴在心梗后心衰中的作用研究
- 批准号:82300434
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
胸腺肽α-1介导凋亡小体RNA改善DC功能增强TNBC化疗后抗肿瘤免疫应答的机制研究
- 批准号:82303959
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
LSD1通过使组蛋白H3K4位点去甲基化促进自噬参与肾小管上皮细胞凋亡和肾脏纤维化的机制研究
- 批准号:82300769
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
相似海外基金
Development of miR-27a* for the Treatment of Head and Neck Squamous Cell Carcinoma
开发 miR-27a* 用于治疗头颈鳞状细胞癌
- 批准号:
10752726 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别:
Regulation of KRAS plasma membrane targeting by defined glycosphingolipids.
通过特定的鞘糖脂调节 KRAS 质膜靶向。
- 批准号:
10718459 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别:
Project 1: Overcoming therapeutic resistance in pancreatic cancer through epigenetic reprogramming
项目1:通过表观遗传重编程克服胰腺癌的治疗耐药性
- 批准号:
10629063 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别:
Immunoepigenetic targeting of MHC regulators in FAP
FAP 中 MHC 调节因子的免疫表观遗传学靶向
- 批准号:
10677375 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别:
Defining cell intrinsic and extrinsic regulators of ferroptosis in pancreatic cancer
定义胰腺癌铁死亡的细胞内在和外在调节因子
- 批准号:
10679812 - 财政年份:2023
- 资助金额:
$ 31.1万 - 项目类别: